Humana Inc. (HUM) Cash Flow Statement

The negative OCF/NI ratio of -0.61 in 2026Q2 suggests that underwriting cash generation is not keeping pace with earnings, potentially due to timing of premium receipts versus claim payments. This contrasts with the prior quarter's positive OCF of $1.3B, indicating volatility in float dynamics that investors should monitor.

The consistent quarter-over-quarter increase in claims paid—from $25.1B in 2024Q1 to $35.4B in 2026Q2—reflects both membership growth and potentially higher utilization or cost inflation. This trend may pressure underwriting margins despite premium increases, and the negative operating cash flow in 2026Q2 suggests that cash outflows for claims are growing faster than premium inflows.

The consistent pattern of buying and selling securities—with net sales in most quarters—suggests that Humana is actively managing its investment portfolio to generate liquidity or rebalance. However, the lack of realized investment income data limits deeper analysis, but the balanced activity implies no significant cash drain from portfolio operations.

Dividend payments have been stable around $107-109M per quarter, representing a modest payout relative to net income. Buybacks have been minimal, with the largest being $717M in 2024Q1, suggesting management is preserving capital. Given the negative operating cash flow in 2026Q2, the dividend appears covered by investment sales or existing cash, but sustainability warrants monitoring if OCF remains negative.

The OCF/NI ratio of -0.61 in 2026Q2 indicates that reported earnings are not being converted into cash, possibly due to timing differences in receivables or payables. This divergence may be influenced by reserve releases that boost net income without corresponding cash inflows, as suggested by prior income statement analysis. Investors should scrutinize the quality of earnings and the sustainability of this gap.